ORIGINAL ARTICLEReduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic diseaseCresswell, A. C.; Sisley, K.*; Laws, D.; Parsons, M. A.; Rennie, I. G.; Murray, A. K.Author Information Institute of Cancer Studies, G Floor, Medical School, Beech Hill Road, Sheffield, UK (A. C. Cresswell, A. K. Murray). Department of Ophthalmology and Orthoptics, O Floor, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK. Tel: (+44) 114 2713199; Fax: (+44) 114 2766381; Email: [email protected] (K. Sisley, M. A. Parsons, I. G. Rennie). Department of Probability and Statistics, I Floor, Hicks Building, Houndsfield Road, Sheffield, UK (D. Laws). (Received 31 July 2000; accepted in revised form 4 December 2000) *To whom correspondence should be addressed Melanoma Research: June 2001 - Volume 11 - Issue 3 - p 275-281 Buy Abstract In order to determine the effects of the loss or reduced expression of molecules associated with antigen presentation (transporter associated with antigen presentation [TAP]-1, TAP-2, low molecular weight protein [LMP]-2 and LMP-7), we examined the expression of these molecules in primary uveal melanoma lesions. Paraffin-embedded sections from 29 primary uveal melanoma lesions were analysed for expression of TAP-1, TAP-2, LMP-2 and LMP-7 using specific primary antibodies followed by a three-stage immunoperoxidase technique. Microscopic examination was undertaken to determine differences in expression of these molecules on the tumour and the surrounding stroma. Overall, 72% (21 out of 29) of the tumours showed some loss or reduced expression of TAP-1, TAP-2, LMP-2 and/or LMP-7. Statistical analysis of these results showed that progression to metastatic disease was strongly associated with reduced expression of TAP-1 (P<0.05) and TAP-2 (P <0.01), taking patient age, tumour site and histology into account. We conclude that the reduced expression of molecules important in eliciting an immune response, such as TAP-1 and TAP-2, may facilitate the metastatic spread of uveal melanoma lesions and may have important implications for prospective immunotherapy. © 2001 Lippincott Williams & Wilkins, Inc.